The focus of cancer therapy is moving towards precision medicine. However, very few efficacious therapies are available for sarcomas. There is a clear unmet need for new therapies for the broad and heterogeneous group of soft tissue sarcomas. We are committed to delivering innovative therapeutic options for patients who have no specific therapies or have failed all currently available options.
Sartar exploits principles of precision medicine, drug repurposing and reformulation to provide efficacious cancer therapies faster to the global markets.